Compare Expeditors International of Wshngtn Inc (EXPD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Expeditors International of Wshngtn Inc trades at $195.87 (market cap $25.37B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Expeditors International of Wshngtn Inc is far larger — about 26.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Expeditors International of Wshngtn Inc pays a 0.83% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 44 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EXPD | MRVI | |
|---|---|---|
Market Cap | $25.37B | $972.90M |
Volume | 1,236,812 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $196.38 | $9.00 |
52-Week Low | $117.35 | $2.83 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $24.90B | $1.08B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $196.38, up 1.54% today, with a bullish technical signal from moving averages and strong profitability metrics including a 42.6% ROE. Recent quarters show consistent earnings beats, and cash flow improved to a positive $166 million in 2025. News highlights efficiency initiatives and AI's impact on freight markets, supporting positive momentum.
The stock's outlook is mixed; fundamentals are solid with revenue growth to $12.0B projected for 2026, but valuation is elevated at a P/E of 28.4, and analyst consensus is cautious with a $179.43 price target below current levels. Risks include reliance on freight demand cycles and competitive pressures in logistics.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
